The HIF pathway as a therapeutic target

Drug Discovery Today
Kirsty S Hewitson, Christopher J Schofield

Abstract

Hypoxia-inducible factor (HIF) is an alpha,beta-heterodimeric transcription factor that mediates cellular responses to low oxygen concentration via the transcriptional activation of specific genes involved in both tumorogenesis and angiogenesis. Manipulation of the HIF pathway has potential use for the treatment of ischemic disease and cancer. Unlike HIF-beta, which is constitutively expressed, the levels and activity of the HIF-alpha subunit are regulated by processes involving posttranslational hydroxylation, catalyzed by Fe(II)- and 2-oxoglutarate-dependent oxygenases. This review focuses on the HIF pathway as a therapeutic target.

Citations

Oct 24, 2007·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·David R Mole, Peter J Ratcliffe
Mar 24, 2006·Breast Cancer Research and Treatment·Sebastian F SchoppmannPeter Birner
Aug 7, 2010·Targeted Oncology·Bristi Basu, Tim Eisen
Apr 5, 2011·Biochemistry·Evren SabanMichael J Knapp
Dec 14, 2012·Journal of Medicinal Chemistry·Ivanhoe K H LeungTimothy D W Claridge
Feb 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Diana TrentinJeffrey A Hubbell
Sep 17, 2009·Antioxidants & Redox Signaling·Simon NagelChristopher J Schofield
Aug 5, 2009·Antioxidants & Redox Signaling·David R Mole
Jan 26, 2010·Antioxidants & Redox Signaling·Orly WeinrebMoussa B H Youdim
Dec 23, 2009·Nucleic Acids Research·Martijn van HagenAlfred C O Vertegaal
Jun 27, 2008·Neuroreport·Insook KimYoung Soo Ahn
Jun 15, 2007·The British Journal of Ophthalmology·Farzin ForooghianLee Timms
Jul 27, 2011·Therapeutic Advances in Medical Oncology·P G CorrieK Ahmad Zaki
Feb 9, 2012·Lipids in Health and Disease·Jize Zhang, Defa Li
Aug 11, 2006·Journal of Cell Science·Amina A Qutub, Aleksander S Popel
Mar 15, 2006·Kidney & Blood Pressure Research·Christian RosenbergerSamuel N Heyman
Apr 13, 2011·Chemical Society Reviews·Ida Karin Nordgren, Ali Tavassoli
Jan 14, 2011·Immunopharmacology and Immunotoxicology·V Prabhu, C Guruvayoorappan
Nov 10, 2009·Expert Review of Anticancer Therapy·Bristi BasuPippa Corrie
Jul 8, 2005·Expert Review of Proteomics·Miguel A Esteban, Patrick H Maxwell
Mar 30, 2011·Journal of Inorganic Biochemistry·Evren SabanMichael J Knapp
Aug 24, 2010·Trends in Biochemical Sciences·Christoph Loenarz, Christopher J Schofield
Sep 25, 2009·Bioorganic & Medicinal Chemistry Letters·Jasmin MecinovićChristopher J Schofield
May 14, 2008·Advanced Drug Delivery Reviews·Christian R Mayer, Raffi Bekeredjian
Apr 16, 2008·British Journal of Haematology·Thomas G SmithPeter J Ratcliffe
Sep 1, 2007·Journal of Neurochemistry·David J LombRobert S Freeman
Jun 30, 2006·Biochemical and Biophysical Research Communications·Georgia G BraliouGeorge Simos
Sep 15, 2004·Drug Discovery Today·David Lando
Sep 9, 2015·Chemical Communications : Chem Comm·C C ThinnesC J Schofield

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Journal of Cellular Physiology
Stefan A M PaulNicola J Mabjeesh
Bioorganic & Medicinal Chemistry Letters
David R MoleChristopher J Schofield
Nature Reviews. Molecular Cell Biology
Christopher J Schofield, Peter J Ratcliffe
© 2021 Meta ULC. All rights reserved